1-35893694-CCTT-C
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PM4_SupportingPP5
The NM_012199.5(AGO1):c.539_541delTCT(p.Phe180del) variant causes a disruptive inframe deletion change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: not found (cov: 32)
Consequence
AGO1
NM_012199.5 disruptive_inframe_deletion
NM_012199.5 disruptive_inframe_deletion
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 7.82
Genes affected
AGO1 (HGNC:3262): (argonaute RISC component 1) This gene encodes a member of the argonaute family of proteins, which associate with small RNAs and have important roles in RNA interference (RNAi) and RNA silencing. This protein binds to microRNAs (miRNAs) or small interfering RNAs (siRNAs) and represses translation of mRNAs that are complementary to them. It is also involved in transcriptional gene silencing (TGS) of promoter regions that are complementary to bound short antigene RNAs (agRNAs), as well as in the degradation of miRNA-bound mRNA targets. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. A recent study showed this gene to be an authentic stop codon readthrough target, and that its mRNA could give rise to an additional C-terminally extended isoform by use of an alternative in-frame translation termination codon. [provided by RefSeq, Nov 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 4 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PM4
Nonframeshift variant in NON repetitive region in NM_012199.5. Strenght limited to Supporting due to length of the change: 1aa.
PP5
Variant 1-35893694-CCTT-C is Pathogenic according to our data. Variant chr1-35893694-CCTT-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 521576.We mark this variant Likely_pathogenic, oryginal submissions are: {Uncertain_significance=2, Pathogenic=3, Likely_pathogenic=3}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
AGO1 | NM_012199.5 | c.539_541delTCT | p.Phe180del | disruptive_inframe_deletion | 5/19 | ENST00000373204.6 | NP_036331.1 | |
AGO1 | NM_001317122.2 | c.539_541delTCT | p.Phe180del | disruptive_inframe_deletion | 5/19 | NP_001304051.1 | ||
AGO1 | NM_001317123.2 | c.314_316delTCT | p.Phe105del | disruptive_inframe_deletion | 5/19 | NP_001304052.1 | ||
AGO1 | XM_011541236.3 | c.539_541delTCT | p.Phe180del | disruptive_inframe_deletion | 5/19 | XP_011539538.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
AGO1 | ENST00000373204.6 | c.539_541delTCT | p.Phe180del | disruptive_inframe_deletion | 5/19 | 1 | NM_012199.5 | ENSP00000362300.4 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:9Uncertain:2
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Pathogenic:2Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing;provider interpretation | Geisinger Autism and Developmental Medicine Institute, Geisinger Health System | Aug 03, 2017 | This 10 year old male has a history of autism spectrum disorder, epilepsy, growth hormone deficiency, hypothyroidism, and ADHD combined type. Patient has had multiple EEGs that reportedly showed centrotemporal spikes that were considered epileptiform, though no seizures have been noted. He has reportedly had two normal MRIs. He is heterozygous for a de novo variant (c.539_541delTCT) in AGO1, which causes an in-frame deletion of one amino acid, phenylalanine 180. This variant is absent from gnomAD. This is a gene of uncertain significance; no known human disorders have been clearly associated with this gene. He is also heterozygous for a nonsense POLG variant that was paternally inherited. His father is reportedly unaffected. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 06, 2024 | In-frame deletion of one amino acid in a non-repeat region; Not observed in large population cohorts (gnomAD); In silico analysis supports a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 35060114, 34930816) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Aug 17, 2020 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratoire de Génétique Moléculaire, CHU Bordeaux | - | - - |
Neurodevelopmental disorder with language delay and behavioral abnormalities, with or without seizures Pathogenic:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 22, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Sep 20, 2024 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0105 - The mechanism of disease for this gene is not clearly established. This gene is associated with neurodevelopmental disorder with language delay and behavioural abnormalities, with or without seizures (MIM#620292). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0213 - In-frame deletion in a non-repetitive region that has high conservation. (SP) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0600 - Variant is located in the annotated argonaute linker 1 domain (DECIPHER). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been classified as pathogenic or likely pathogenic by multiple clinical laboratories in ClinVar. ClinVar also contains some older entries with VUS classifications. This variant has also been reported in six unrelated de novo individuals with neurodevelopmental disorder with intellectual disability, with four individuals also having seizures (PMID: 35060114, 34930816, 36563181). (SP) 0905 - No published segregation evidence has been identified for this variant. (I) 1007 - No published functional evidence has been identified for this variant. (I) 1203 - This variant has been shown to be de novo in the proband (parental status confirmed) (by trio analysis). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Jan 02, 2025 | - - |
Neurodevelopmental abnormality Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | Department of Genetics, Rouen University Hospital, Normandy Center for Genomic and Personalized Medicine | May 15, 2020 | - - |
Inborn genetic diseases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 19, 2023 | The c.539_541delTCT (p.F180del) alteration, located in coding exon 5 of the AGO1 gene, results from an in-frame TCT deletion at nucleotide positions c.539 to c.541. This results in the deletion of a phenylalanine residue at codon 180. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. The p.F180 amino acid is located in the L1 linker domain, which connects the N-terminal and PAZ domains (Yuan, 2005). The L1 linker domain has been shown to interact with the DNA heteroduplex, guide RNA strands, and complementary DNA target strands (Miyoshi, 2016). Interactions between the L1 linker and the DNA target strand play an important role in DNA silencing activity (Miyoshi, 2016). This alteration is predicted to be deleterious by in silico analysis (Choi, 2012). Based on the available evidence, this alteration is classified as likely pathogenic. - |
See cases Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Genetics Laboratory, UDIAT-Centre Diagnòstic, Hospital Universitari Parc Tauli | Apr 26, 2021 | PM2_supporting;PM4_moderate;PM6_moderate;PP3_supporting - |
Seizure;C0036857:Intellectual disability, severe;C0040822:Tremor;C0085271:Self-injurious behavior;C1837397:Severe global developmental delay Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Sep 07, 2022 | _x000D_ Criteria applied: PS2, PS4_MOD, PM1, PM2_SUP, PM4_SUP - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at